Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review

Manaithiya, A.; Alam, O.; Sharma, V.; Javed Naim, M.; Mittal, S.; Khan, I.A. GPR119 Agonists: Novel Therapeutic Agents for Type 2 Diabetes Mellitus. In: Bioorganic Chemistry; Elsevier Inc.: Amsterdam, 2021, p. 113.

Center for Disease Control and Prevention. What is Diabetes? Available from: https://www.cdc.gov/diabetes/basics/diabetes.html

Goodman, L.S.; Brunton, L.L.; Chabner, B.; Knollmann, B.C. Goodman & Gilman’s pharmacological basis of therapeutics; McGraw-Hill: New York, 2011.

Chatterjee, S.; Khunti, K.; Davies, M.J. Type 2 diabetes. Lancet, 2017, 389(10085), 2239-2251.
[http://dx.doi.org/10.1016/S0140-6736(17)30058-2] [PMID: 28190580]

Foye, W.O.; Lemke, T.L.; Williams, D.A. Foye`s Principles of Medicinal Chemistry;Wolters Kluwer Health/Lippincott Williams & Wilkins:Philadephia, 2013.

Tripathi, K.D. Essentials of Medical Pharmacology, 7th Ed.; Jaypee Brothers Medical Publishers (P) Ltd.: New Delhi, 2013.

Thrower, S.L.; Bingley, P.J. What is type 1 diabetes? Medicine, 2010, 38(11), 592-596.
[http://dx.doi.org/10.1016/j.mpmed.2010.08.003] [PMID: 20061432]

Dowarah, J.; Singh, V.P. Anti-diabetic drugs recent approaches and advancements. Bioorg. Med. Chem., 2020, 28(5), 115263.
[http://dx.doi.org/10.1016/j.bmc.2019.115263] [PMID: 32008883]

Leslie, R.D. Predicting adult-onset autoimmune diabetes: Clarity from complexity. Diabetes, 2010, 59(2), 330-331.
[http://dx.doi.org/10.2337/db09-1620] [PMID: 20103711]

Rother, K.I. Diabetes treatment--bridging the divide. N. Engl. J. Med., 2007, 356(15), 1499-1501.
[http://dx.doi.org/10.1056/NEJMp078030] [PMID: 17429082]

Todd, J.A. Etiology of type 1 diabetes. Immunity, 2010, 32(4), 457-467.
[http://dx.doi.org/10.1016/j.immuni.2010.04.001] [PMID: 20412756]

Bluestone, J.A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature, 2010, 464(7293), 1293-1300.
[http://dx.doi.org/10.1038/nature08933] [PMID: 20432533]

Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5), 1047-1053.
[http://dx.doi.org/10.2337/diacare.27.5.1047] [PMID: 15111519]

Reddy, S.S.K. Diagnosis of Diabetes Mellitus in Older Adults. Clin. Geriatr. Med., 2020, 36(3), 379-384.
[http://dx.doi.org/10.1016/j.cger.2020.04.011] [PMID: 32586468]

Gökçay Canpolat, A.; Şahin, M. Glucose lowering treatment modalities of type 2 Diabetes Mellitus. Adv. Exp. Med. Biol., 2020, 1307, 7-27.
[http://dx.doi.org/10.1007/5584_2020_516] [PMID: 32200500]

Li, Q.; Deng, X.; Jiang, N.; Meng, L.; Xing, J.; Jiang, W.; Xu, Y. Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Eur. J. Med. Chem., 2021, 225, 113765.
[http://dx.doi.org/10.1016/j.ejmech.2021.113765] [PMID: 34399391]

Hu, C.; Jia, W. Therapeutic medications against diabetes: What we have and what we expect. Adv. Drug Deliv. Rev., 2019, 139, 3-15.
[http://dx.doi.org/10.1016/j.addr.2018.11.008] [PMID: 30529309]

Hussain, H.; Abbas, G.; Green, I.R.; Ali, I. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: Patent review (2015-2018). Expert Opin. Ther. Pat., 2019, 29(7), 535-553.
[http://dx.doi.org/10.1080/13543776.2019.1632290] [PMID: 31203700]

Suzuki, R.; Brown, G.A.; Christopher, J.A.; Scully, C.C.G.; Congreve, M. Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 Receptors. J. Med. Chem., 2020, 63(3), 905-927.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00835] [PMID: 31577440]

Jesus, A.R.; Vila-Viçosa, D.; Machuqueiro, M.; Marques, A.P.; Dore, T.M.; Rauter, A.P. Targeting type 2 diabetes with c-glucosyl dihydrochalcones as selective sodium glucose co-transporter 2 (sglt2) inhibitors: Synthesis and biological evaluation. J. Med. Chem., 2017, 60(2), 568-579.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01134] [PMID: 28098449]

Jain, S.; Saraf, S. Type 2 diabetes mellitus-Its global prevalence and therapeutic strategies. Diabetes Metab. Syndr., 2010, 4(1), 48-56.
[http://dx.doi.org/10.1016/j.dsx.2008.04.011]

Galicia-Garcia, U.; Benito-Vicente, A.; Jebari, S.; Larrea-Sebal, A.; Siddiqi, H.; Uribe, K.B.; Ostolaza, H.; Martín, C. Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci., 2020, 21(17), 6275.
[http://dx.doi.org/10.3390/ijms21176275] [PMID: 32872570]

Rank, F.; Nn, J.O.A.; Anson, E.M. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N. Engl. J. Med., 2001, 345(11), 790-797.
[http://dx.doi.org/10.1056/NEJMoa010492] [PMID: 11556298]

Schellenberg, E.S.; Dryden, D.M.; Vandermeer, B.; Ha, C.; Korownyk, C. Lifestyle interventions for patients with and at risk for type 2 diabetes. Ann. Intern. Med., 2013, 159(8), 543-551.
[http://dx.doi.org/10.7326/0003-4819-159-8-201310150-00007] [PMID: 24126648]

Chan, J.C.; Cheung, C.K.; Swaminathan, R.; Nicholls, M.G.; Cockram, C.S. Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad. Med. J., 1993, 69(809), 204-210.
[http://dx.doi.org/10.1136/pgmj.69.809.204] [PMID: 8497435]

McKeigue, P.M.; Shah, B.; Marmot, M.G. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascu-lar risk in South Asians. Lancet, 1991, 337(8738), 382-386.
[http://dx.doi.org/10.1016/0140-6736(91)91164-P] [PMID: 1671422]

Liu, L.L.; Yi, J.P.; Beyer, J.; Mayer-Davis, E.J.; Dolan, L.M.; Dabelea, D.M.; Lawrence, J.M.; Rodriguez, B.L.; Marcovina, S.M.; Waitzfel-der, B.E.; Fujimoto, W.Y. Type 1 and type 2 diabetes in Asian and Pacific Islander U.S. youth. Diabetes Care, 2009, 32(Suppl. 2), S133-S140.
[http://dx.doi.org/10.2337/dc09-S205] [PMID: 19246578]

Sattar, N.; Gill, J.M.R. Type 2 diabetes in migrant south Asians: Mechanisms, mitigation, and management. Lancet Diabetes Endocrinol., 2015, 3(12), 1004-1016.
[http://dx.doi.org/10.1016/S2213-8587(15)00326-5] [PMID: 26489808]

Fuchsberger, C.; Flannick, J.; Teslovich, T.M.; Mahajan, A.; Agarwala, V.; Gaulton, K.J.; Ma, C.; Fontanillas, P.; Moutsianas, L.; McCarthy, D.J.; Rivas, M.A.; Perry, J.R.B.; Sim, X.; Blackwell, T.W.; Robertson, N.R.; Rayner, N.W.; Cingolani, P.; Locke, A.E.; Tajes, J.F.; Highland, H.M.; Dupuis, J.; Chines, P.S.; Lindgren, C.M.; Hartl, C.; Jackson, A.U.; Chen, H.; Huyghe, J.R.; van de Bunt, M.; Pearson, R.D.; Kumar, A.; Müller-Nurasyid, M.; Grarup, N.; Stringham, H.M.; Gamazon, E.R.; Lee, J.; Chen, Y.; Scott, R.A.; Below, J.E.; Chen, P.; Huang, J.; Go, M.J.; Stitzel, M.L.; Pasko, D.; Parker, S.C.J.; Varga, T.V.; Green, T.; Beer, N.L.; Day-Williams, A.G.; Ferreira, T.; Fingerlin, T.; Horikoshi, M.; Hu, C.; Huh, I.; Ikram, M.K.; Kim, B.J.; Kim, Y.; Kim, Y.J.; Kwon, M.S.; Lee, J.; Lee, S.; Lin, K.H.; Maxwell, T.J.; Na-gai, Y.; Wang, X.; Welch, R.P.; Yoon, J.; Zhang, W.; Barzilai, N.; Voight, B.F.; Han, B.G.; Jenkinson, C.P.; Kuulasmaa, T.; Kuusisto, J.; Manning, A.; Ng, M.C.Y.; Palmer, N.D.; Balkau, B.; Stančáková, A.; Abboud, H.E.; Boeing, H.; Giedraitis, V.; Prabhakaran, D.; Gottes-man, O.; Scott, J.; Carey, J.; Kwan, P.; Grant, G.; Smith, J.D.; Neale, B.M.; Purcell, S.; Butterworth, A.S.; Howson, J.M.M.; Lee, H.M.; Lu, Y.; Kwak, S.H.; Zhao, W.; Danesh, J.; Lam, V.K.L.; Park, K.S.; Saleheen, D.; So, W.Y.; Tam, C.H.T.; Afzal, U.; Aguilar, D.; Arya, R.; Aung, T.; Chan, E.; Navarro, C.; Cheng, C.Y.; Palli, D.; Correa, A.; Curran, J.E.; Rybin, D.; Farook, V.S.; Fowler, S.P.; Freedman, B.I.; Griswold, M.; Hale, D.E.; Hicks, P.J.; Khor, C.C.; Kumar, S.; Lehne, B.; Thuillier, D.; Lim, W.Y.; Liu, J.; van der Schouw, Y.T.; Loh, M.; Musani, S.K.; Puppala, S.; Scott, W.R.; Yengo, L.; Tan, S.T.; Taylor, H.A., Jr; Thameem, F.; Wilson, G., Sr; Wong, T.Y.; Njølstad, P.R.; Levy, J.C.; Mangino, M.; Bonnycastle, L.L.; Schwarzmayr, T.; Fadista, J.; Surdulescu, G.L.; Herder, C.; Groves, C.J.; Wieland, T.; Bork-Jensen, J.; Brandslund, I.; Christensen, C.; Koistinen, H.A.; Doney, A.S.F.; Kinnunen, L.; Esko, T.; Farmer, A.J.; Hakaste, L.; Hodgkiss, D.; Kravic, J.; Lyssenko, V.; Hollensted, M.; Jørgensen, M.E.; Jørgensen, T.; Ladenvall, C.; Justesen, J.M.; Käräjämäki, A.; Kriebel, J.; Rathmann, W.; Lannfelt, L.; Lauritzen, T.; Narisu, N.; Linneberg, A.; Melander, O.; Milani, L.; Neville, M.; Orho-Melander, M.; Qi, L.; Qi, Q.; Roden, M.; Rolandsson, O.; Swift, A.; Rosengren, A.H.; Stirrups, K.; Wood, A.R.; Mihailov, E.; Blancher, C.; Carneiro, M.O.; Maguire, J.; Poplin, R.; Shakir, K.; Fennell, T.; DePristo, M.; Hrabé de Angelis, M.; Deloukas, P.; Gjesing, A.P.; Jun, G.; Nilsson, P.; Murphy, J.; Onofrio, R.; Thorand, B.; Hansen, T.; Meisinger, C.; Hu, F.B.; Isomaa, B.; Karpe, F.; Liang, L.; Peters, A.; Huth, C.; O’Rahilly, S.P.; Pal-mer, C.N.A.; Pedersen, O.; Rauramaa, R.; Tuomilehto, J.; Salomaa, V.; Watanabe, R.M.; Syvänen, A.C.; Bergman, R.N.; Bharadwaj, D.; Bottinger, E.P.; Cho, Y.S.; Chandak, G.R.; Chan, J.C.N.; Chia, K.S.; Daly, M.J.; Ebrahim, S.B.; Langenberg, C.; Elliott, P.; Jablonski, K.A.; Lehman, D.M.; Jia, W.; Ma, R.C.W.; Pollin, T.I.; Sandhu, M.; Tandon, N.; Froguel, P.; Barroso, I.; Teo, Y.Y.; Zeggini, E.; Loos, R.J.F.; Small, K.S.; Ried, J.S.; DeFronzo, R.A.; Grallert, H.; Glaser, B.; Metspalu, A.; Wareham, N.J.; Walker, M.; Banks, E.; Gieger, C.; Ingelsson, E. Im, H.K.; Illig, T.; Franks, P.W.; Buck, G.; Trakalo, J.; Buck, D.; Prokopenko, I.; Mägi, R.; Lind, L.; Farjoun, Y.; Owen, K.R.; Gloyn, A.L.; Strauch, K.; Tuomi, T.; Kooner, J.S.; Lee, J.Y.; Park, T.; Donnelly, P.; Morris, A.D.; Hattersley, A.T.; Bowden, D.W.; Collins, F.S.; Atzmon, G.; Chambers, J.C.; Spector, T.D.; Laakso, M.; Strom, T.M.; Bell, G.I.; Blangero, J.; Duggirala, R.; Tai, E.S.; McVean, G.; Hanis, C.L.; Wilson, J.G.; Seielstad, M.; Frayling, T.M.; Meigs, J.B.; Cox, N.J.; Sladek, R.; Lander, E.S.; Gabriel, S.; Burtt, N.P.; Mohlke, K.L.; Meitinger, T.; Groop, L.; Abecasis, G.; Florez, J.C.; Scott, L.J.; Morris, A.P.; Kang, H.M.; Boehnke, M.; Altshuler, D.; McCarthy, M.I. The genetic architecture of type 2 diabetes. Nature, 2016, 536(7614), 41-47.
[http://dx.doi.org/10.1038/nature18642] [PMID: 27398621]

McCarthy, M.I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med., 2010, 363(24), 2339-2350.
[http://dx.doi.org/10.1056/NEJMra0906948] [PMID: 21142536]

Bellou, Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. PLoS One, 2018, 13(3), 1-27.

Hillier, T.A.; Pedula, K.L. Complications in young Adults with early-onset type 2 diabetes: Losing the relative protection of youth. Diabetes Care, 2003, 26(11), 2999-3005.
[http://dx.doi.org/10.2337/diacare.26.11.2999]

Weinstein, A.R.; Sesso, H.D.; Lee, I.M.; Cook, N.R.; Manson, J.E.; Buring, J.E.; Gaziano, J.M. Relationship of physical activity vs body mass index with type 2 diabetes in women. JAMA, 2004, 292(10), 1188-1194.
[http://dx.doi.org/10.1001/jama.292.10.1188] [PMID: 15353531]

Fu, Z.; Gilbert, E.R.; Liu, D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr. Diabetes Rev., 2013, 9(1), 25-53.
[http://dx.doi.org/10.2174/157339913804143225] [PMID: 22974359]

Halban, P.A. Proinsulin processing in the regulated and the constitutive secretory pathway. Diabetologia, 1994, 37(S2), S65-S72.
[http://dx.doi.org/10.1007/BF00400828] [PMID: 7821742]

Henry, W.L. Perspectives in diabetes. J. Natl. Med. Assoc., 1962, 54(4), 476-478.
[PMID: 13906557]

Halban, P.A.; Polonsky, K.S.; Bowden, D.W.; Hawkins, M.A.; Ling, C.; Mather, K.J.; Powers, A.C.; Rhodes, C.J.; Sussel, L.; Weir, G.C. β-cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment. Diabetes Care, 2014, 37(6), 1751-1758.
[http://dx.doi.org/10.2337/dc14-0396] [PMID: 24812433]

Moneva, M.H.; Dagogo-Jack, S. Multiple drug targets in the management of type 2 diabetes. Curr. Drug Targets, 2002, 3(3), 203-221.
[http://dx.doi.org/10.2174/1389450023347803] [PMID: 12041735]

Weir, G.C.; Laybutt, D.R.; Kaneto, H.; Bonner-Weir, S.; Sharma, A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes, 2001, 50(2)(Suppl. 1), S154-S159.
[http://dx.doi.org/10.2337/diabetes.50.2007.S154] [PMID: 11272180]

Kim, M.K.; Cheong, Y.H.; Lee, S.H.; Kim, T.H.; Jung, I.H.; Chae, Y.; Lee, J.H.; Yang, E.K.; Park, H.; Yang, J.S.; Hong, K.W. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression. Biomed. Pharmacother., 2021, 144(10), 112324.
[http://dx.doi.org/10.1016/j.biopha.2021.112324] [PMID: 34678732]

Yamamoto, W.R.; Bone, R.N.; Sohn, P.; Syed, F.; Reissaus, C.A.; Mosley, A.L.; Wijeratne, A.B.; True, J.D.; Tong, X.; Kono, T.; Evans-Molina, C. Endoplasmic reticulum stress alters ryanodine receptor function in the murine pancreatic β cell. J. Biol. Chem., 2019, 294(1), 168-181.
[http://dx.doi.org/10.1074/jbc.RA118.005683] [PMID: 30420428]

Liu, M.; Weiss, M.A.; Arunagiri, A.; Yong, J.; Rege, N.; Sun, J.; Haataja, L.; Kaufman, R.J.; Arvan, P. Biosynthesis, structure, and folding of the insulin precursor protein. Diabetes Obes. Metab., 2018, 20(Suppl. 2), 28-50.
[http://dx.doi.org/10.1111/dom.13378] [PMID: 30230185]

Höppener, J.W.; Ahrén, B.; and Lips, C.J. 2000, Islet amyloid and type 2 diabetes mellitus. New England J. Med., 343(6), 411-419.
[http://dx.doi.org/10.1056/nejm200008103430607]

Westermark, P. Amyloid and polypeptide hormones: What is their interrelationship? Amyloid, 1994, 1(1), 47-60.
[http://dx.doi.org/10.3109/13506129409148624]

Flannick, J.; Thorleifsson, G.; Beer, N.L.; Jacobs, S.B.R.; Grarup, N.; Burtt, N.P.; Mahajan, A.; Fuchsberger, C.; Atzmon, G.; Benedikts-son, R.; Blangero, J.; Bowden, D.W.; Brandslund, I.; Brosnan, J.; Burslem, F.; Chambers, J.; Cho, Y.S.; Christensen, C.; Douglas, D.A.; Duggirala, R.; Dymek, Z.; Farjoun, Y.; Fennell, T.; Fontanillas, P.; Forsén, T.; Gabriel, S.; Glaser, B.; Gudbjartsson, D.F.; Hanis, C.; Han-sen, T.; Hreidarsson, A.B.; Hveem, K.; Ingelsson, E.; Isomaa, B.; Johansson, S.; Jørgensen, T.; Jørgensen, M.E.; Kathiresan, S.; Kong, A.; Kooner, J.; Kravic, J.; Laakso, M.; Lee, J.Y.; Lind, L.; Lindgren, C.M.; Linneberg, A.; Masson, G.; Meitinger, T.; Mohlke, K.L.; Molven, A.; Morris, A.P.; Potluri, S.; Rauramaa, R.; Ribel-Madsen, R.; Richard, A.M.; Rolph, T.; Salomaa, V.; Segrè, A.V.; Skärstrand, H.; Steint-horsdottir, V.; Stringham, H.M.; Sulem, P.; Tai, E.S.; Teo, Y.Y.; Teslovich, T.; Thorsteinsdottir, U.; Trimmer, J.K.; Tuomi, T.; Tuomileh-to, J.; Vaziri-Sani, F.; Voight, B.F.; Wilson, J.G.; Boehnke, M.; McCarthy, M.I.; Njølstad, P.R.; Pedersen, O.; Groop, L.; Cox, D.R.; Ste-fansson, K.; Altshuler, D. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat. Genet., 2014, 46(4), 357-363.
[http://dx.doi.org/10.1038/ng.2915] [PMID: 24584071]

del Bosque-Plata, L.; Martínez-Martínez, E.; Espinoza-Camacho, M.Á.; Gragnoli, C. The role of TCF7L2 in type 2 diabetes. Diabetes, 2021, 70(6), 1220-1228.
[http://dx.doi.org/10.2337/db20-0573] [PMID: 34016596]

Lyssenko, V.; Nagorny, C.L.F.; Erdos, M.R.; Wierup, N.; Jonsson, A.; Spégel, P.; Bugliani, M.; Saxena, R.; Fex, M.; Pulizzi, N.; Isomaa, B.; Tuomi, T.; Nilsson, P.; Kuusisto, J.; Tuomilehto, J.; Boehnke, M.; Altshuler, D.; Sundler, F.; Eriksson, J.G.; Jackson, A.U.; Laakso, M.; Marchetti, P.; Watanabe, R.M.; Mulder, H.; Groop, L. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat. Genet., 2009, 41(1), 82-88.
[http://dx.doi.org/10.1038/ng.288] [PMID: 19060908]

Steinthorsdottir, V.; Thorleifsson, G.; Reynisdottir, I.; Benediktsson, R.; Jonsdottir, T.; Walters, G.B.; Styrkarsdottir, U.; Gretarsdottir, S.; Emilsson, V.; Ghosh, S.; Baker, A.; Snorradottir, S.; Bjarnason, H.; Ng, M.C.Y.; Hansen, T.; Bagger, Y.; Wilensky, R.L.; Reilly, M.P.; Adeyemo, A.; Chen, Y.; Zhou, J.; Gudnason, V.; Chen, G.; Huang, H.; Lashley, K.; Doumatey, A.; So, W.Y.; Ma, R.C.Y.; Andersen, G.; Borch-Johnsen, K.; Jorgensen, T.; van Vliet-Ostaptchouk, J.V.; Hofker, M.H.; Wijmenga, C.; Christiansen, C.; Rader, D.J.; Rotimi, C.; Gurney, M.; Chan, J.C.N.; Pedersen, O.; Sigurdsson, G.; Gulcher, J.R.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat. Genet., 2007, 39(6), 770-775.
[http://dx.doi.org/10.1038/ng2043] [PMID: 17460697]

Voight, B.F.; Scott, L.J.; Steinthorsdottir, V.; Morris, A.P.; Dina, C.; Welch, R.P.; Zeggini, E.; Huth, C.; Aulchenko, Y.S.; Thorleifsson, G.; McCulloch, L.J.; Ferreira, T.; Grallert, H.; Amin, N.; Wu, G.; Willer, C.J.; Raychaudhuri, S.; McCarroll, S.A.; Langenberg, C.; Hofmann, O.M.; Dupuis, J.; Qi, L.; Segrè, A.V.; van Hoek, M.; Navarro, P.; Ardlie, K.; Balkau, B.; Benediktsson, R.; Bennett, A.J.; Blagieva, R.; Boerwinkle, E.; Bonnycastle, L.L.; Boström, K.B.; Bravenboer, B.; Bumpstead, S.; Burtt, N.P.; Charpentier, G.; Chines, P.S.; Cornelis, M.; Couper, D.J.; Crawford, G.; Doney, A.S.F.; Elliott, K.S.; Elliott, A.L.; Erdos, M.R.; Fox, C.S.; Franklin, C.S.; Ganser, M.; Gieger, C.; Grarup, N.; Green, T.; Griffin, S.; Groves, C.J.; Guiducci, C.; Hadjadj, S.; Hassanali, N.; Herder, C.; Isomaa, B.; Jackson, A.U.; Johnson, P.R.V.; Jørgensen, T.; Kao, W.H.L.; Klopp, N.; Kong, A.; Kraft, P.; Kuusisto, J.; Lauritzen, T.; Li, M.; Lieverse, A.; Lindgren, C.M.; Lys-senko, V.; Marre, M.; Meitinger, T.; Midthjell, K.; Morken, M.A.; Narisu, N.; Nilsson, P.; Owen, K.R.; Payne, F.; Perry, J.R.B.; Petersen, A.K.; Platou, C.; Proença, C.; Prokopenko, I.; Rathmann, W.; Rayner, N.W.; Robertson, N.R.; Rocheleau, G.; Roden, M.; Sampson, M.J.; Saxena, R.; Shields, B.M.; Shrader, P.; Sigurdsson, G.; Sparsø, T.; Strassburger, K.; Stringham, H.M.; Sun, Q.; Swift, A.J.; Thorand, B.; Ti-chet, J.; Tuomi, T.; van Dam, R.M.; van Haeften, T.W.; van Herpt, T.; van Vliet-Ostaptchouk, J.V.; Walters, G.B.; Weedon, M.N.; Wijmen-ga, C.; Witteman, J.; Bergman, R.N.; Cauchi, S.; Collins, F.S.; Gloyn, A.L.; Gyllensten, U.; Hansen, T.; Hide, W.A.; Hitman, G.A.; Hofman, A.; Hunter, D.J.; Hveem, K.; Laakso, M.; Mohlke, K.L.; Morris, A.D.; Palmer, C.N.A.; Pramstaller, P.P.; Rudan, I.; Sijbrands, E.; Stein, L.D.; Tuomilehto, J.; Uitterlinden, A.; Walker, M.; Wareham, N.J.; Watanabe, R.M.; Abecasis, G.R.; Boehm, B.O.; Campbell, H.; Daly, M.J.; Hattersley, A.T.; Hu, F.B.; Meigs, J.B.; Pankow, J.S.; Pedersen, O.; Wichmann, H.E.; Barroso, I.; Florez, J.C.; Frayling, T.M.; Groop, L.; Sladek, R.; Thorsteinsdottir, U.; Wilson, J.F.; Illig, T.; Froguel, P.; van Duijn, C.M.; Stefansson, K.; Altshuler, D.; Boehnke, M.; McCarthy, M.I. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet., 2010, 42(7), 579-589.
[http://dx.doi.org/10.1038/ng.609] [PMID: 20581827]

Travers, M.E.; Mackay, D.J.G.; Dekker Nitert, M.; Morris, A.P.; Lindgren, C.M.; Berry, A.; Johnson, P.R.; Hanley, N.; Groop, L.C.; McCarthy, M.I.; Gloyn, A.L. Insights into the molecular mechanism for type 2 diabetes susceptibility at the KCNQ1 locus from temporal changes in imprinting status in human islets. Diabetes, 2013, 62(3), 987-992.
[http://dx.doi.org/10.2337/db12-0819] [PMID: 23139357]

Sandhu, M.S.; Weedon, M.N.; Fawcett, K.A.; Wasson, J.; Debenham, S.L.; Daly, A.; Lango, H.; Frayling, T.M.; Neumann, R.J.; Sherva, R.; Blech, I.; Pharoah, P.D.; Palmer, C.N.A.; Kimber, C.; Tavendale, R.; Morris, A.D.; McCarthy, M.I.; Walker, M.; Hitman, G.; Glaser, B.; Permutt, M.A.; Hattersley, A.T.; Wareham, N.J.; Barroso, I. Common variants in WFS1 confer risk of type 2 diabetes. Nat. Genet., 2007, 39(8), 951-953.
[http://dx.doi.org/10.1038/ng2067] [PMID: 17603484]

Pulido, R. Retraction for Berthier et al. PINK1 regulates histone H3 trimethylation and gene expression by interaction with the polycomb protein EED/WAIT1. Proc. Natl. Acad. Sci., 2014, 111(45), 16225.
[http://dx.doi.org/10.1073/pnas.1419354111] [PMID: 25331905]

Haghvirdizadeh, P; Mohamed, Z; Abdullah, NA; Haghvirdizadeh, P; Haerian, MS; Haerian, BS KCNJ11: Genetic polymorphisms and risk of diabetes mellitus. J Diabetes Res., 2015, 2015

Gloyn, A.L.; Reimann, F.; Girard, C.; Edghill, E.L.; Proks, P.; Pearson, E.R.; Temple, I.K.; Mackay, D.J.G.; Shield, J.P.H.; Freedenberg, D.; Noyes, K.; Ellard, S.; Ashcroft, F.M.; Gribble, F.M.; Hattersley, A.T. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum. Mol. Genet., 2005, 14(7), 925-934.
[http://dx.doi.org/10.1093/hmg/ddi086] [PMID: 15718250]

Small, K.S.; Todorčević, M.; Civelek, M.; El-Sayed Moustafa, J.S.; Wang, X.; Simon, M.M.; Fernandez-Tajes, J.; Mahajan, A.; Horikoshi, M.; Hugill, A.; Glastonbury, C.A.; Quaye, L.; Neville, M.J.; Sethi, S.; Yon, M.; Pan, C.; Che, N.; Viñuela, A.; Tsai, P.C.; Nag, A.; Buil, A.; Thorleifsson, G.; Raghavan, A.; Ding, Q.; Morris, A.P.; Bell, J.T.; Thorsteinsdottir, U.; Stefansson, K.; Laakso, M.; Dahlman, I.; Arner, P.; Gloyn, A.L.; Musunuru, K.; Lusis, A.J.; Cox, R.D.; Karpe, F.; McCarthy, M.I. Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition. Nat. Genet., 2018, 50(4), 572-580.
[http://dx.doi.org/10.1038/s41588-018-0088-x] [PMID: 29632379]

Shahvazian, E.; Mahmoudi, M.B.; Farashahi Yazd, E.; Gharibi, S.; Moghimi, B. HosseinNia, P.; Mirzaei, M. The KLF14 Variant is Asso-ciated with Type 2 Diabetes and HbA1C Level. Biochem. Genet., 2021, 59(2), 574-588.
[http://dx.doi.org/10.1007/s10528-020-10015-w] [PMID: 33389382]

Chiefari, E.; Tanyolaç, S.; Paonessa, F.; Pullinger, C.R.; Capula, C.; Iiritano, S.; Mazza, T.; Forlin, M.; Fusco, A.; Durlach, V.; Durlach, A.; Malloy, M.J.; Kane, J.P.; Heiner, S.W.; Filocamo, M.; Foti, D.P.; Goldfine, I.D.; Brunetti, A. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA, 2011, 305(9), 903-912.
[http://dx.doi.org/10.1001/jama.2011.207] [PMID: 21364139]

Silander, K.; Mohlke, K.L.; Scott, L.J.; Peck, E.C.; Hollstein, P.; Skol, A.D.; Jackson, A.U.; Deloukas, P.; Hunt, S.; Stavrides, G.; Chines, P.S.; Erdos, M.R.; Narisu, N.; Conneely, K.N.; Li, C.; Fingerlin, T.E.; Dhanjal, S.K.; Valle, T.T.; Bergman, R.N.; Tuomilehto, J.; Watanabe, R.M.; Boehnke, M.; Collins, F.S. Genetic variation near the hepatocyte nuclear factor-4 α gene predicts susceptibility to type 2 diabetes. Diabetes, 2004, 53(4), 1141-1149.
[http://dx.doi.org/10.2337/diabetes.53.4.1141] [PMID: 15047633]

Boden, G. Obesity and free fatty acids. Endocrinol. Metab. Clin. North Am., 2008, 37(3), 635-646.
[http://dx.doi.org/10.1016/j.ecl.2008.06.007] [PMID: 18775356]

Portha, B; Chavey, A; Movassat, J Early-life origins of type 2 diabetes: Fetal programming of the beta-cell mass. Exp. Diabetes Res., 2011, 2011, 105076.
[http://dx.doi.org/10.1155/2011/105076]

Finol, F.; Parra, N.; Parra, M. PPAR- g agonists and their role in type 2 diabetes mellitus management. Am. J. Ther., 2010, 17(3), 274-283.

Matveyenko, A.V.; Butler, P.C. Relationship between β-cell mass and diabetes onset. Diabetes Obes. Metab., 2008, 10(4)(Suppl. 4), 23-31.
[http://dx.doi.org/10.1111/j.1463-1326.2008.00939.x] [PMID: 18834430]

Pan, A.; Lucas, M.; Sun, Q.; van Dam, R.M.; Franco, O.H.; Manson, J.E.; Willett, W.C.; Ascherio, A.; Hu, F.B. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch. Intern. Med., 2010, 170(21), 1884-1891.
[http://dx.doi.org/10.1001/archinternmed.2010.356] [PMID: 21098346]

Nouwen, A.; Winkley, K.; Twisk, J.; Lloyd, C.E.; Peyrot, M.; Ismail, K.; Pouwer, F. Type 2 diabetes mellitus as a risk factor for the onset of depression: A systematic review and meta-analysis. Diabetologia, 2010, 53(12), 2480-2486.
[http://dx.doi.org/10.1007/s00125-010-1874-x] [PMID: 20711716]

Holman, R.R.; Paul, S.K.; Bethel, M.A.; Matthews, D.R.; Neil, H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 2008, 359(15), 1577-1589.
[http://dx.doi.org/10.1056/NEJMoa0806470] [PMID: 18784090]

Feng, X.; Scott, A.; Wang, Y.; Wang, L.; Zhao, Y.; Doerner, S.; Satake, M.; Croniger, C.M.; Wang, Z. PTPRT regulates high-fat diet-induced obesity and insulin resistance. PLoS One, 2014, 9(6), e100783.
[http://dx.doi.org/10.1371/journal.pone.0100783] [PMID: 24949727]

Boden, G. Free fatty acids FFA a link between obesity and insulin resistance. Front. Biosci., 1998, 3(4), A272.
[http://dx.doi.org/10.2741/A272] [PMID: 9450985]

Yehualashet, A.S. Toll-like receptors as a potential drug target for diabetes mellitus and diabetes-associated complications. Diabetes. Diabetes Metab. Syndr. Obes., 2020, 13, 4763-4777.
[http://dx.doi.org/10.2147/DMSO.S274844] [PMID: 33311992]

Ichimura, A.; Hasegawa, S.; Kasubuchi, M.; Kimura, I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front. Pharmacol., 2014, 5(11), 1-7.
[http://dx.doi.org/10.3389/fphar.2014.00236]

Rangwala, S.M.; Lazar, M.A. Peroxisome proliferator-activated receptor g in diabetes and metabolism. Trends Pharmacol. Sci., 2004, 25(6), 331-336.
[http://dx.doi.org/10.1016/j.tips.2004.03.012]

Sun, J.; Qu, C.; Wang, Y.; Huang, H.; Zhang, M.; Zou, W. Type 2 diabetes mellitus and protein-tyrosine phosphatase 1b. J. Diabetes. Metab. Disord. Control, 2016, 3(8), 180-183.
[http://dx.doi.org/10.15406/jdmdc.2016.03.00096]

Singh, S.; Singh Grewal, A.; Grover, R.; Sharma, N.; Chopra, B.; Kumar Dhingra, A.; Arora, S.; Redhu, S.; Lather, V. Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disorders. Bioorg. Chem., 2022, 121(4), 105626.
[http://dx.doi.org/10.1016/j.bioorg.2022.105626] [PMID: 35255350]

Grewal, A.S.; Bhardwaj, S.; Pandita, D.; Lather, V.; Sekhon, B.S. Updates on aldose reductase inhibitors for management of diabetic complica-tions and non-diabetic diseases. Mini Rev. Med. Chem., 2016, 16(2), 120-162.

Padhi, S.; Nayak, A.K.; Behera, A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed. Pharmacother., 2020, 131, 110708.
[http://dx.doi.org/10.1016/j.biopha.2020.110708] [PMID: 32927252]

Bhattacharya, S.; Rathore, A.; Parwani, D.; Mallick, C.; Asati, V.; Agarwal, S.; Rajoriya, V.; Das, R.; Kashaw, S.K. An exhaustive perspec-tive on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent. Eur. J. Med. Chem., 2020, 204, 112523.
[http://dx.doi.org/10.1016/j.ejmech.2020.112523] [PMID: 32717480]

Deacon, CF Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol., 2020, 16(11), 642-653.
[http://dx.doi.org/10.1038/s41574-020-0399-8]

Overton, H.A.; Fyfe, M.C.T.; Reynet, C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol., 2008, 153(Suppl. 1), S76-S81.

Zhao, J.; Zhao, Y.; Hu, Y.; Peng, J. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disea-se. Cell. Mol. Biol. Lett., 2021, 26(1), 32.
[http://dx.doi.org/10.1186/s11658-021-00276-7]

Dhayal, S.; and Morgan, N.G. 2010. The significance of GPR119 agonists as a future treatment for type 2 diabetes. Drug News Perspect., 2010, 23(7), 418-424.

Im, D.S. 2021. GPR119 and GPR55 as receptors for fatty acid ethanolamides, oleoylethanolamide and palmitoylethanolamide. Int. J. Mol. Sci., 2021, 22(3), 1034.

Tyurenkov, I.N.; Kurkin, D.V.; Bakulin, D.A.; Volotova, E. V Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. Front. Endocrinol., 2018, 9, 543.
[http://dx.doi.org/10.3389/fendo.2018.00543]

Ritter, K.; Buning, C.; Halland, N.; Po, C.; Schwink, L.G. G protein-coupled receptor 119 (gpr119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J. Med. Chem., 2016, 59(8), 3579-3592.

Godlewski, G.; Offertáler, L.; Wagner, J.A. Kunos, G Receptors for acylethanolamides — GPR55 and GPR119. Prostaglandins Other Lipid Mediat., 2009, 89, 105-111.

Gpr, S Mutation-guided unbiased modeling of the fat resource mutation-guided unbiased modeling of the fat sensor GPR119 for high-yield agonist screening. Struct. Des., 2015, 1-10.

Yang, J.W. Kim, HS Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes Obes. Metab., 2018, 20(2), 257-269.

Highlights, M. G-protein-coupled receptors: New approaches to maximise the impact of GPCRS in drug discovery. Expert Opin. Ther. Targets, 2004, 8(2), 165-170.
[http://dx.doi.org/10.1517/14728222.8.2.165]

Fredriksson, R.; Gloriam, D.E.I.; Lagerstro, M.C. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett., 2003, 554(3), 381-388.
[http://dx.doi.org/10.1016/S0014-5793(03)01196-7]

liang, C.Z.; Jones, RM.; He, H. A Role for -Cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing Glucose- Dependent insulin release. 2015, 148(5), 2601-2609.

Odori, S.; Hosoda, K.; Tomita, T.; Fujikura, J.; Kusakabe, T.; Kawaguchi, Y.; Doi, R.; Takaori, K.; Ebihara, K.; Sakai, Y.; Uemoto, S.; Nakao, K. GPR119 expression in normal human tissues and islet cell tumors: Evidence for its islet-gastrointestinal distribution, expres-sion in pancreatic beta and alpha cells, and involvement in islet function. Metabolism, 2013, 62(1), 70-78.
[http://dx.doi.org/10.1016/j.metabol.2012.06.010] [PMID: 22883930]

Ahlkvist, L.; Brown, K.; Ahre, B. Upregulated insulin secretion in insulin-resistant mice : evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion. Endocr. Connect., 2013, 2(2), 69-78.
[http://dx.doi.org/10.1530/EC-12-0079]

Engelstoft, M.S.; Norn, C.; Hauge, M.; Holliday, N.D.; Elster, L. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119 Tables of Links. Br. J. Pharmacol., 2014, 171(24), 5774-5789.
[http://dx.doi.org/10.1111/bph.12877]

Ohishi, T.; Yoshida, S. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin. Investig. Drugs, 2012, 21(3), 321-328.
[http://dx.doi.org/10.1517/13543784.2012.657797]

Oh, D.Y.; Olefsky, J.M. G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat. Rev. Drug Discov., 2016, 15(3), 161-172.
[http://dx.doi.org/10.1038/nrd.2015.4] [PMID: 26822831]

Hamaguchi, K.; Gaskins, H.R.; Leiter, E.H. NIT-1, a pancreatic β-cell line established from a transgenic NOD/Lt mouse. Diabetes, 1991, 40(7), 842-849.
[http://dx.doi.org/10.2337/diab.40.7.842] [PMID: 1647994]

Miyazaki, S.; Tashiro, F.; Tsuchiya, T.; Sasaki, K.; Miyazaki, J. Establishment of a long-term stable β-cell line and its application to analyze the effect of Gcg expression on insulin secretion. Sci. Rep., 2021, 11(1), 477.
[http://dx.doi.org/10.1038/s41598-020-79992-7] [PMID: 33414495]

Santerre, RF; Cook, RA Crisel, Insulin synthesis in a clonal cell line of simian virus 40-transformed hamster pancreatic beta cells. Proc Natl Acad Sci, 1981, 78(7 I), 4339-4343.

Efrat, S.; Linde, S.; Kofod, H.; Spector, D.; Delannoy, M.; Grant, S.; Hanahan, D.; Baekkeskov, S. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc. Natl. Acad. Sci., 1988, 85(23), 9037-9041.
[http://dx.doi.org/10.1073/pnas.85.23.9037] [PMID: 2848253]

Miyazaki, J.I.; Araki, K.; Yamato, E.; Ikegami, H.; Asano, T.; Shibasaki, Y.; Oka, Y.; Yamamura, K.I. Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology, 1990, 127(1), 126-132.
[http://dx.doi.org/10.1210/endo-127-1-126] [PMID: 2163307]

Asfari, M.; Janjic, D.; Meda, P.; Li, G.; Halban, P.A.; Wollheim, C.B. Establishment Differentiated. Endocrinology, 1992, 130(1), 167-178.
[http://dx.doi.org/10.1210/endo.130.1.1370150] [PMID: 1370150]

Noda, M.; Komatsu, M.; Sharp, G.W.G. The betaHC-9 pancreatic β-cell line preserves the characteristics of progenitor mouse islets. Diabetes, 1996, 45(12), 1766-1773.
[http://dx.doi.org/10.2337/diab.45.12.1766] [PMID: 8922364]

Kobayashi, M.; Yamato, E.; Tanabe, K.; Tashiro, F.; Miyazaki, S.; Miyazaki, J. Functional analysis of novel candidate regulators of insulin secretion in the MIn6 mouse pancreatic β cell line. PLoS One, 2016, 11(3), e0151927.
[http://dx.doi.org/10.1371/journal.pone.0151927] [PMID: 26986842]

Berner, A.; Bachmann, M.; Bender, C.; Pfeilschifter, J.; Christen, U.; Mühl, H. Though active on RINm5F insulinoma cells and cultured pancreatic islets, recombinant IL-22 fails to modulate cytotoxicity and disease in a protocol of streptozotocin-induced experimental diabe-tes. Front. Pharmacol., 2016, 6(1), 317.
[http://dx.doi.org/10.3389/fphar.2015.00317] [PMID: 26793108]

Gpr, F.F.A.; Engelstoft, M.S. GPR119, a major enteroendocrine sensor of dietary triglyceride metabolites coacting in synergy with FFA1 (GPR40). Endocrinology, 2016, 157(12), 4561-4569.
[http://dx.doi.org/10.1210/en.2016-1334]

Hansen, K.B.; Rosenkilde, M.M.; Knop, F.K. 2-Oleoyl glycerol Is a GPR119 agonist and signals GLP-1 release in humans. J. Clin. Endocrinol. Metab., 2011, 96(9), E1409-E1417.
[http://dx.doi.org/10.1210/jc.2011-06472011]

Kleberg, K.; Nielsen, L.L.; Stuhr-hansen, N.; Nielsen, J. Evaluation of the immediate vascular stability of lipoprotein lipase-generated 2-monoacylglycerol in mice. Biofactors, 2014, 40(6), 596-602.
[http://dx.doi.org/10.1002/biof.1189]

Tough, I.R.; Forbes, S.; Herzog, H.; Jones, R.M.; Schwartz, T.W.; Cox, H.M. Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa. Endocrinology, 2018, 159(4), 1704-1717.
[http://dx.doi.org/10.1210/en.2017-03172]

liang, C.Z; Carroll, C.; Chen, R. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol. Endocrinol., 2010, 24(1), 161-170.

Soga, T.; Ohishi, T.; Matsui, T. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun., 2005, 326(4), 744-751.
[http://dx.doi.org/10.1016/j.bbrc.2004.11.120]

Kogure, R.; Toyama, K.; Hiyamuta, S.; Kojima, I.; Takeda, S. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. Biochem. Biophys. Res. Commun., 2011, 416(1-2), 58-63.
[http://dx.doi.org/10.1016/j.bbrc.2011.10.141] [PMID: 22079287]

Semple, G.; Ren, A.; Fioravanti, B.; Pereira, G.; Calderon, I.; Choi, K.; Xiong, Y.; Shin, Y.J.; Gharbaoui, T.; Sage, C.R.; Morgan, M.; Xing, C.; Chu, Z.L.; Leonard, J.N.; Grottick, A.J.; Al-Shamma, H.; Liang, Y.; Demarest, K.T.; Jones, R.M. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg. Med. Chem. Lett., 2011, 21(10), 3134-3141.
[http://dx.doi.org/10.1016/j.bmcl.2011.03.007] [PMID: 21444206]

Semple, G.; Fioravanti, B.; Pereira, G. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J. Med. Chem., 2008, 51(17), 5172-5175.
[http://dx.doi.org/10.1021/jm8006867]

liang, C.Z; Carroll, C.; Alfonso, J. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology, 2008, 149(5), 2038-2047.
[http://dx.doi.org/10.1210/en.2007-0966]

Marty, V.N.; Farokhnia, M.; Munier, J.J.; Mulpuri, Y. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front. Neurosci., 2020, 14, 599646.
[http://dx.doi.org/10.3389/fnins.2020.599646]

Negoro, K.; Yonetoku, Y.; Maruyama, T.; Yoshida, S.; Takeuchi, M.; Ohta, M. Synthesis and structure–activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists. Bioorg. Med. Chem., 2012, 20(7), 2369-2375.
[http://dx.doi.org/10.1016/j.bmc.2012.02.006] [PMID: 22365911]

Shah, U.; Kowalski, T.J. GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders. In: Vitamins & Hormones, 1st ed; Elsevier Inc., 2010, pp. 84.
[http://dx.doi.org/10.1016/B978-0-12-381517-0.00016-3]

Zhu, X.; Huang, D.; Lan, X. European Journal of Medicinal Chemistry The fi rst pharmacophore model for potent G protein-coupled re-ceptor 119 agonist. Eur. J. Med. Chem., 2011, 46(7), 2901-2907.
[http://dx.doi.org/10.1016/j.ejmech.2011.04.014] [PMID: 21524831]

Kang, S-U. GPR119 agonists: A promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discov. Today, 2013, 18(23-24), 1309-1315.
[http://dx.doi.org/10.1016/j.drudis.2013.09.011]

Hansen, H.S.; Rosenkilde, M.M.; Holst, J.J.; Schwartz, T.W. GPR119 as a fat sensor. Trends Pharmacol. Sci., 2012, 33(7), 374-381.
[http://dx.doi.org/10.1016/j.tips.2012.03.014]

Semple, G.; Lehmann, J.; Wong, A.; Ren, A.; Bruce, M.; Shin, Y.J.; Sage, C.R.; Morgan, M.; Chen, W.C.; Sebring, K.; Chu, Z.L.; Leonard, J.N.; Al-Shamma, H.; Grottick, A.J.; Du, F.; Liang, Y.; Demarest, K.; Jones, R.M. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg. Med. Chem. Lett., 2012, 22(4), 1750-1755.
[http://dx.doi.org/10.1016/j.bmcl.2011.12.092] [PMID: 22264481]

Watada, H.; Shiramoto, M.; Myobatake, Y.; Taguchi, T. G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic b -cells in Japanese type 2 diabetes mellitus patients. J. Diabetes Investig., 2019, 10(1), 84-93.
[http://dx.doi.org/10.1111/jdi.12849]

Kato, M.; Furuie, H.; Kamiyama, E.; Shiosakai, K. Safety and pharmacokinetics of DS-8500a, a novel GPR119 agonist, after multiple oral doses in healthy japanese males. Clin. Drug Investig., 2018, 38(6), 519-525.
[http://dx.doi.org/10.1007/s40261-018-0633-5]

Matsumoto, K.; Yoshitomi, T.; Ishimoto, Y.; Tanaka, N.; Takahashi, K. DS-8500a, an orally available g protein-coupled receptor 119 ago-nist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. J. Pharmacol. Exp. Ther., 2018, 367(3), 509-517.
[http://dx.doi.org/10.1124/jpet.118.250019]

Katamreddy, S. R.; Carpenter, A. J.; Ammala, C. E.; Boros, E. E.; Brashear, R. L.; Briscoe, C. P.; Bullard, S. R.; Caldwell, R. D.; Conlee, C. R.; Croom, D. K.; Hart, S. M.; Heyer, D. O.; Johnson, P. R.; Kashatus, J. A.; Minick, D. J.; Peckham, G. E.; Ross, S. A.; Roller, S. G.; Sa-mano, V. A.; Sauls, H. R. Discovery of 6,7- Dihydro-5H-Pyrrolo[2,3-A]Pyrimidines as orally available G protein- coupled receptor 119 agonists. J. Med. Chem., 2012, 55(24), 10972-10994.
[http://dx.doi.org/10.1021/jm301404a]

Hothersall, J.D.; Bussey, C.E.; Brown, A.J.; Scott, J.S.; Dale, I.; Rawlins, P. Sustained wash-resistant receptor activation responses of GPR119 agonists. Eur. J. Pharmacol., 2015, 762, 430-442.
[http://dx.doi.org/10.1016/j.ejphar.2015.06.031] [PMID: 26101059]

Kim, H.J.; Choi, J.Y.; Che, X. G protein‐coupled receptor 119 is involved in RANKL‐induced osteoclast differentiation and fusion. J. Cell. Physiol., 2019, 234(7), 11490-11499.
[http://dx.doi.org/10.1002/jcp.27805]

Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Oshima, H.; Yonetoku, Y.; Shibasaki, M. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem. Biophys. Res. Commun., 2010, 402(2), 280-285.
[http://dx.doi.org/10.1016/j.bbrc.2010.10.015] [PMID: 20937249]

Yoshida, S.; Ohishi, T.; Matsui, T. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function. Diabetes Obesity and Metab., 2011, 13(1), 34-41.

Yoshida, S.; Tanaka, H.; Oshima, H. Biochemical and Biophysical Research Communications AS1907417, a novel GPR119 agonist, as an insulinotropic and b -cell preservative agent for the treatment of type 2 diabetes. Biochem. Biophys. Res. Commun., 2010, 400(4), 745-751.
[http://dx.doi.org/10.1016/j.bbrc.2010.08.141] [PMID: 20816753]

Oshima, H.; Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Yonetoku, Y.; Shibasaki, M.; Uchiyama, Y. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice. Life Sci., 2013, 92(2), 167-173.
[http://dx.doi.org/10.1016/j.lfs.2012.11.015] [PMID: 23246743]

Free, C.; Christopherson, J. Chen, Q Activation of GPR119 stimulates human β-cell replication and neogenesis in humanized mice with functional human islets. J. Diabetes Res., 2016, 2016, 1620821.
[http://dx.doi.org/10.1155/2016/1620821]

Overton, H.A.; Babbs, A.J. Doel, SM Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small- molecule hypophagic agents. Cell Metab., 2006, 3(3), 167-175.

GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity. Expert Opin. Drug Discov., 2008, 3(4), 403-413.

Kim, S.R.; Kim, D.H.; Park, S.H. In vivo efficacy of HD0471953 : A novel gpr119 agonist for the treatment of type 2 diabetes mellitus. J. Diabetes Res., 2013, 2013, 269569.

Kim, S.; Kim, D.H. HD047703, a new promising anti-diabetic drug candidate: In vivo preclinical studies. Biomol. Ther., 2014, 22(5), 400-405.

Kim, T.Y. seok, HY.; Hwa, C. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus. Arch. Pharm. Res., 2014, 37(5), 671-678.

Huan, Y.; Jiang, Q.; Li, G. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Scientific. Reports, 2017, 7(5), 1-11.

Harada, K.; Mizukami, J.; Watanabe, T.; Mori, G.; Ubukata, M.; Suwa, K.; Fukuda, S.; Negoro, T.; Sato, M.; Inaba, T. Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure. Bioorg. Med. Chem. Lett., 2019, 29(3), 373-379.
[http://dx.doi.org/10.1016/j.bmcl.2018.12.041] [PMID: 30587450]

Syed, S.K.; Bui, H.H. Beavers, LS Regulation of GPR119 receptor activity with endocannabinoid-like lipids Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am. J. Physiol. Endocrinol. Metab., 2012, 303(12), E1469-E1478.

Polli, J.W.; Hussey, E.; Bush, M. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clini-cal study design. Xenobiotica, 2013, 43(6), 498-508.
[http://dx.doi.org/10.3109/00498254.2012.739719]

Agonist, A.G.P.R.; Gao, J.; Tian, L. Stimulating b -cell replication and improving islet graft function by AR231453, AGPR119 agonist. TPS, 2011, 43(9), 3217-3220.
[PMID: 22099761]

Gao, J.; Tian, L.; Weng, G. Stimulating beta cell replication and improving islet graft function by GPR119 agonists. Transpl. Int., 2011, 24, 1124-1134.
[http://dx.doi.org/10.1111/j.1432-2277.2011.01332.x]

Fang, Y.; Yang, Z.; Gundeti, S.; Lee, J.; Park, H. Novel 5- Nitropyrimidine Derivatives Bearing Endo-Azabicyclic Alcohols/ Amines as Potent GPR119 Agonists. Bioorg. Med. Chem., 2017, 25(1), 254-260.
[http://dx.doi.org/10.1016/j.bmc.2016.10.030]

Chen, J.; Sang, Z.; Li, L.; He, L.; Ma, L. Discovery of 5-methyl-2- (4- ((4- (methylsulfonyl) benzyl)oxy) phenyl) -4- (piperazin-1-yl) pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity. Mol. Divers., 2017, 21(3), 637-654.

Yang, Z.; Fang, Y.; Park, H. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. Bioorg. Med. Chem. Lett., 2017, 27(11), 2515-2519.
[http://dx.doi.org/10.1016/j.bmcl.2017.03.092] [PMID: 28408218]

Fang, Y.; Xu, J.; Li, Z.; Yang, Z.; Xiong, L.; Jin, Y.; Wang, Q.; Xie, S.; Zhu, W.; Chang, S. Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes. Bioorg. Med. Chem., 2018, 26(14), 4080-4087.
[http://dx.doi.org/10.1016/j.bmc.2018.06.035] [PMID: 30100020]

Fang, Y.; Zhang, S.; Wu, W.; Liu, Y.; Yang, J.; Li, Y.; Li, M.; Dong, H.; Jin, Y.; Liu, R.; Yang, Z. Design and synthesis of tetrahydropyri-dopyrimidine derivatives as dual GPR119 and DPP-4 modulators. Bioorg. Chem., 2020, 94(10), 103390.
[http://dx.doi.org/10.1016/j.bioorg.2019.103390] [PMID: 31662212]

Koshizawa, T.; Morimoto, T.; Watanabe, G.; Watanabe, T.; Yamasaki, N.; Sawada, Y.; Fukuda, T.; Okuda, A.; Shibuya, K.; Ohgiya, T. Optimization of a novel series of potent and orally bioavailable GPR119 agonists. Bioorg. Med. Chem. Lett., 2017, 27(15), 3249-3253.
[http://dx.doi.org/10.1016/j.bmcl.2017.06.034] [PMID: 28648463]